the DBL report

Issue #127, July 2022

An Official Accompaniment to the Alberta Drug Benefit List (ADBL) produced by Alberta Blue Cross

The Expert Committee on Drug Evaluation and Therapeutics (ECDET)

In this issue:

Brief Summary of Drug Review Activities

The Expert Committee on Drug Evaluation and Therapeutics met on May 16 & 17, 2022. The Committee reviewed Manufacturer submissions for twenty-four (24) Drug Products for potential listing, or change in listing, on the *ADBL*. The Committee also considered information for a number of supplementary assessments of the coverage status of fourteen (14) Drug Products.

In addition to Drug Products reviewed by the Expert Committee, twenty-seven (27) Drug Products and Devices underwent Expedited Review for listing on the *ADBL* effective June 1, 2022, and fifty (50) Drug Products and Devices underwent Expedited Review for listing on the *ADBL* effective July 1, 2022.

The following are highlights of recent changes to the *ADBL* and other topics of general interest. A complete list of changes, as well as the full *ADBL* may be accessed at https://www.ab.bluecross.ca/dbl/publications.php

Highlights of Products Originally Reviewed via the Common Drug Review (CDR)

The following Drug Product was reviewed by CDR and the Expert Committee and added to the *ADBL* effective July 1, 2022:

- **DUPIXENT* 200 mg & 300 mg injection syringes** (dupilumab) (SAV) via Special Authorization (SA) for the indication of Atopic Dermatitis

A complete list of changes, as well as the full ADBL may be accessed at https://www.ab.bluecross.ca/dbl/publications.php.
Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).*

ABC 81171 (07/2022)

Highlights of Interchangeable (IC) Drug Products Added

Addition of the following Entry IC Drug Product to the *ADBL* has resulted in the creation of New IC Groupings, effective June 1, 2022:

- **PMS-FLUTICASONE HFA 125 mcg/dose metered dose aerosol** (fluticasone propionate) (PMS)

Addition of the following Entry IC Drug Products to the *ADBL* have resulted in the creation of New IC Groupings, effective July 1, 2022:

- **APO-SAXAGLIPTIN* 2.5 mg & 5 mg tablets** (saxagliptin hydrochloride) (APX) via Step Therapy/SA
- **CLONIDINE HYDROCHLORIDE 0.025 mg tablets** (various brands: SDZ & MAR)
- **JAMP CLOXACILLIN 250 mg & 500 mg capsules** (cloxacillin sodium) (JPC)
- **LURASIDONE HYDROCHLORIDE 20 mg, 40 mg, 60 mg & 80 mg tablets** (various brands: JPC, PMS, SDZ & TAR)
- **LURASIDONE HYDROCHLORIDE 120 mg tablets** (various brands: PMS & TAR)
- **METHOTREXATE SUBCUTANEOUS 15 mg/0.3 mL, 17.5 mg/0.35 mL, 20 mg/0.4 mL, 22.5 mg/0.45 mL & 25 mg/0.5 mL injection syringes** (methotrexate sodium) (AHI)
- **TARO-TICAGRELOR* 90 mg tablet** (ticagrelor) (TAR) via Restricted Benefit/SA
- **TERIFLUNOMIDE* 14 mg tablets** (various brands: AHI, APX, JPC, MTR, MAR, NTP, PMS, SDZ & TEV) via SA

Highlights of Drug Products Added

The following Drug Products were reviewed by the Expert Committee and added to the *ADBL* effective July 1, 2022:

- **ODAN-SODIUM POLYSTYRENE SULFONATE 250 mg/mL suspension** (sodium polystyrene sulfonate) (ODN)
- **ZENHALE* 100 mcg/5 mcg/dose & 200 mcg/5 mcg/dose metered dose aerosols** (mometasone furoate/ formoterol fumarate dihydrate) (ORC) via Step Therapy/SA

Highlights of Biosimilar Drug Products Added

The following Biosimilar Drug Products were added to the *ADBL* effective June 1, 2022:

- **SIMLANDI* 40 mg/0.4 mL auto-injector pen** (adalimumab) (JPC) via SA for the indications of Rheumatoid Arthritis (RA), Plaque Psoriasis (PsO), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Hidradenitis Suppurativa (HS), Crohn's Disease (CD), Ulcerative Colitis (UC) and Polyarticular Juvenile Idiopathic Arthritis (pJIA)
- **YUFLYMA* 40 mg/0.4 mL injection pen** (adalimumab) (CHC) via SA for the indications of RA, PsO, PsA, AS, HS, CD, UC and pJIA

The following Biosimilar Drug Products were added to the *ADBL* effective July 1, 2022:

- **HULIO* 20 mg/0.4 mL injection syringe** (adalimumab) (BGP) via SA for the indication of pJIA
- **SIMLANDI* 40 mg/0.4 mL prefilled syringe** (adalimumab) (JPC) via SA for the indications of RA, PsA, AS, HS, CD, PsO, pJIA & UC
- **SIMLANDI* 80 mg/0.8 mL prefilled syringe** (adalimumab) (JPC) via SA for the indications of HS, CD, PsO & UC

Special Authorization Criteria Changes

The Special Authorization criteria for coverage for the following Drug Products have been revised effective June 1, 2022:

- **FINGOLIMOD HYDROCHLORIDE* 0.5 mg capsules** (various brands: APX, JPC, MAR, MYP, NOV, PMS, SDZ, TAR & TEV)
- **LEMTRADA* 12 mg/1.2 mL injection** (alemtuzumab) (GZM)
- **MAVENCLAD* 10 mg tablet** (cladribine) (SRO)
- **TYSABRI* 20 mg/mL (15 mL vial) injection** (natalizumab) (BIO)

The Special Authorization criteria for coverage for the following Drug Products have been revised effective July 1, 2022:

- **AJOVY* 225 mg/1.5 mL auto-injector & injection syringes** (fremanezumab) (TMP)

A complete list of changes, as well as the full ADBL may be accessed at https://www.ab.bluecross.ca/dbl/publications.html.

Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).*

ABC 81171 (07/2022)